Results 291 to 300 of about 436,330 (367)

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy [PDF]

Peipei Chen, Junyu Long, Jiayang Zhang, Fucun Xie, Wei Wu, Zhuang Tian, Yuanqiang Zhang, Kang Yu   +7 more
openalex   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

International Journal of Dermatology, EarlyView.
Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis   +8 more
wiley   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. [PDF]

Rheumatol Ther
Youssef P, Ciciriello S, Tahir T, Leadbetter J, Butcher B, Calao M, Walsh N, O'Sullivan C, Smith T, Littlejohn G.   +9 more
europepmc   +1 more source

No Increased Risk of Thromboembolic Events During 6‐Month Treatment With Baricitinib in Patients With Alopecia Areata

International Journal of Dermatology, EarlyView.
Giacomo Caldarola, Antonietta Ferretti, Lorenzo Maria Pinto, Leonardo Di Gennaro, Eleonora De Luca, Gennaro Marco Falco, Clara De Simone, Raimondo De Cristofaro, Ketty Peris   +8 more
wiley   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. [PDF]

Clin Gastroenterol Hepatol
Ahuja D, Yeh KH, Patel SB, Lee HH, Goodwin SW, Solitano V, Ma C, Ananthakrishnan AN, Singh N, Jairath V, Xu R, Singh S.   +11 more
europepmc   +1 more source

Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort

International Journal of Dermatology, EarlyView.
Alonso García‐Núñez, Antonio Alcalá Ramírez Del Puerto, Roberto Daza‐García, María Teresa Monserrat‐García, Mercedes Morillo‐Andújar, Javier Jesús Domínguez‐Cruz, Román Barabash‐Neila   +6 more
wiley   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source